-
Cryofocus Medtech Partners with Guangzhou Medical University Hospital for Cryoballoon Ablation R&D
•
Cryofocus Medtech (Shanghai) Co., Ltd. (HKG: 6922), a Shanghai-based leader in cryoablation treatment, and the First Affiliated Hospital of Guangzhou Medical University have entered into a collaborative agreement to contribute to the Guangzhou Lab’s project establishment and management. Guangzhou Lab is a cutting-edge research institution dedicated to the prevention and…
-
Kintor Pharmaceutical Initiates Phase II/III Trial for KX-826 Tincture 1.0% in Treating Male Androgenetic Alopecia
•
Kintor Pharmaceutical Ltd (HKG: 9939), a biopharmaceutical company based in China, has announced the commencement of patient enrollment in a pivotal Phase II/III study for its KX-826 tincture 1.0%. The study aims to evaluate the efficacy and safety of the treatment in adult males with androgenetic alopecia (AGA) in China.…
-
Novocure’s Optune Lua Wins FDA Approval for mNSCLC Treatment in Combination with Immunotherapies
•
Novocure (NASDAQ: NVCR), a Swiss firm renowned for its pioneering Tumor Treating Fields (TTFields) cancer therapy, has received marketing approval from the US Food and Drug Administration (FDA) for its Optune Lua device. This portable device is now cleared for use in combination with PD-1/PD-L1 inhibitors or docetaxel to treat…
-
Servier and HUST Forge Partnership to Cultivate Innovative Therapies through SHINEDocs Program
•
French pharmaceutical company Servier has joined forces with Huazhong University of Science and Technology (HUST), a leading academic institution in China, to include HUST’s PhD students in the Servier Highlighting Innovation through its NEtwork of PhD students and Post-Docs (SHINEDocs) program. This strategic partnership aims to bridge the gap between…
-
Innovent Biologics’ Picankibart Achieves Positive Results in Phase II UC Study
•
Innovent Biologics, Inc. (HKG: 1801), a leading biopharmaceutical company based in China, has announced that its Phase II clinical trial for picankibart, an anti-IL-23p19 antibody injection, has successfully met its primary endpoint in Chinese patients with moderately to severely active ulcerative colitis (UC). The multi-center, randomized, double-blinded, placebo-controlled study (NCT05377580)…
-
Bayer AG Launches China Innovation Hub to Boost Local R&D and Global Integration
•
Bayer AG (ETR: BAYN), a German multinational pharmaceutical and life sciences giant, has announced the launch of the China Center of Innovation and Partnership (CIIP) at the SH-INNO incubator in Shanghai. The incubator, established in August this year, is a collaborative effort between Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607),…
-
Lexicon Pharmaceuticals Strikes Licensing Deal with Viatris for Global Expansion of Sotagliflozin
•
Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) has entered into a licensing agreement with Viatris Inc. (NASDAQ: VTRS), a deal that extends Viatris’s exclusive commercialization rights to sotagliflozin in all markets outside the United States and Europe across all indications. Lexicon Pharmaceuticals retains the exclusive rights to commercialize sotagliflozin within the US…
-
Johnson & Johnson’s Nipocalimab Shows Promise in Treating Adolescent Myasthenia Gravis in Phase II/III Trial
•
Johnson & Johnson (J&J, NYSE: JNJ), a US pharmaceutical giant, has reported encouraging outcomes from its Phase II/III clinical trial, Vibrance-MG, which evaluated the efficacy of nipocalimab in treating adolescents with generalized myasthenia gravis (gMG) who tested positive for anti-AChR antibodies. The study successfully achieved its primary and secondary endpoints,…
-
Alphamab Oncology and CSPC Pharma’s KN026 Phase III Trial for Breast Cancer Gets NMPA Approval
•
Alphamab Oncology (HKG: 9966) and CSPC Pharma (HKG: 1093) have jointly announced that their Phase III clinical study application for the combination of HER2 bispecific antibody KN026 and nab-paclitaxel HB1801 (Study Protocol Number: KN026-004) has received approval from the National Medical Products Administration (NMPA) Drug Evaluation Center (CDE) for neoadjuvant…
-
Boehringer Ingelheim Pledges USD 5 Million to WHO Foundation for Global Healthcare Advancement
•
Boehringer Ingelheim (BI), a leading German pharmaceutical company, has joined forces with the World Health Organization (WHO) Foundation in a significant pledge to enhance access to quality healthcare services for all, particularly targeting vulnerable groups in the Americas who face a heightened risk of suicide. The commitment involves a substantial…
-
J&J Reports Q3 2024 Revenue Growth, Raises Full-Year Guidance on Strong Pipeline Progress
•
Johnson & Johnson (J&J, NYSE: JNJ) has released its financial report for the third quarter of 2024, announcing revenues of USD 22.47 billion for the period, marking a 5.2% increase year-on-year in constant currency terms. This growth was comprised of USD 4.58 billion in innovative medicine sales, which expanded by…
-
Shanghai Junshi Biosciences’ Toripalimab Wins Marketing Approvals in India and Hong Kong for Nasopharyngeal Carcinoma
•
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180), a leading biotech company based in China, has announced that it has received marketing approvals in India and Hong Kong for its drug toripalimab, used for the treatment of recurrent or metastatic nasopharyngeal carcinoma (NPC). The drug will be marketed under…
-
Eli Lilly Launches Medical Innovation Center and Gateway Labs in Beijing to Accelerate Clinical Trials and R&D
•
Eli Lilly & Co. (NYSE: LLY), a leading pharmaceutical corporation in the US, has announced the opening of the Lilly China Medical Innovation Center in Beijing, China, along with plans to establish a Lilly Gateway Labs (LGL). These initiatives are aimed at enhancing clinical trials and bolstering drug research and…
-
Jiangsu Hengrui Resubmits Application for Camrelizumab Combo in HCC to FDA
•
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a prominent pharmaceutical company based in China, has announced a new attempt at a market filing with the US Food and Drug Administration (FDA) for its programmed death-1 (PD-1) monoclonal antibody (mAb) camrelizumab, in combination with the small-molecule targeted cancer therapy apatinib, as…
-
Innovec Biotherapeutics’ IVB103 Gene Therapy for nAMD Receives Clinical Trial Approval from China’s CDE
•
Beijing InnoVec Biotherapeutics Inc., a leading gene therapy company based in China, has announced that it has received clinical trial approval from the Center for Drug Evaluation (CDE) for its IVB103 treatment for neovascular (wet) age-related macular degeneration (nAMD). This follows a clinical trial approval for the same indication in…
-
Aficamten Market Filing Accepted by China’s CDE for Hypertrophic Cardiomyopathy Treatment
•
CORXEL, formerly known as Ji Xing Pharmaceuticals and Cytokinetics Inc (CYTK, NASDAQ: CYTK) have achieved a significant milestone with the acceptance of their market filing for aficamten by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in China. Aficamten, a next-generation cardiac myosin inhibitor, is…
-
Jiangsu Hengrui’s Hetrombopag Olamine Receives NMPA Review for Severe Aplastic Anemia Indication
•
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has announced that the National Medical Products Administration (NMPA) has accepted for review another indication approval filing for its drug candidate, hetrombopag olamine. This new indication is for the use of hetrombopag olamine in combination with…
-
Hinova Pharmaceuticals Gets NMPA Green Light for HP568 Clinical Study in Breast Cancer
•
Hinova Pharmaceuticals Inc. (SHA: 688302), a biotech firm based in Chengdu, has announced that it has received approval from the National Medical Products Administration (NMPA) to commence a clinical study for its drug candidate HP568. This new drug is intended for the treatment of estrogen receptor (ER) positive, human epidermal…
-
Boehringer Ingelheim Partners with Circle Pharma to Develop First-in-Class Cyclin Inhibitor
•
Boehringer Ingelheim (BI), a leading German pharmaceutical company, has announced a research collaboration and license agreement with Circle Pharma, a US-based firm. This strategic partnership aims to develop a first-in-class cyclin inhibitor, a novel approach that could halt the growth of cancer cells and offer new hope for patients struggling…
-
TenNor Therapeutics Secures USD 42.16 Million in Series E Financing for Antibacterial Pipeline
•
TenNor Therapeutics, a clinical-stage pharmaceutical company based in China, has announced the successful completion of its Series E financing round, raising RMB 300 million (USD 42.16 million). The financing was co-led by Zhongshan Venture Capital and the AMR Action Fund. The funds raised will be directed towards the late-stage clinical…
